Navigation Links
Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
Date:11/15/2010

39.3% compared to $2.9 million for the same period in 2009. This increase was primarily due to a relative increase in bad debt expense. Selling, general and administrative expenses as a percentage of sales were 39.1% for the third quarter of 2010 compared to 30.9% for the same period in 2009. For the nine months ended September 30, 2010, selling, general and administrative expenses were $11.6 million, an increase of 15.6% compared to $10.1 million in the same period in 2009. This increase was mainly due to the aforementioned increase in bad debt expense. For the nine months ended September 30, 2010, selling, general and administrative expenses as a percentage of sales were 38.8%, compared to 20.9% for the same period in 2009.

As of September 30, 2010, Tiens had $128.5 million of retained earnings and total shareholders' equity of $195.3 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, "We are pleased to report an increase in domestic sales which we believe will continue in the future. Our total revenue decline should be temporary since both our domestic and global affiliated companies have not witnessed significant declines in their overall revenue. We are committed to expanding our international customer base and generating long-term domestic and international growth."

About Tiens Biotech Group (USA), Inc. www.tiens-bio.com

Tiens Biotech Group (USA), Inc. (NYSE AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 54 countries.  Since its establishment, Tiens has developed an
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. Tiens Biotech Group (USA) Reports First Quarter Results
5. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Yongye Biotechnology International Retains CCG Investor Relations
8. ThirdBiotech Announces Kemeta as Newest Sponsor
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
11. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... FL (PRWEB) May 26, 2015 ... Inc. have announced plans for the company’s first cellular ... 2015, followed by a full day, hands-on stem cell ... by J. Victor Garcia Gimenez, M.D., President of Therapeutic ... the medical community’s increasing interest in regenerative medicine and ...
(Date:5/26/2015)...  A simple blood test developed at the University ... Alzheimer,s disease is a step closer to being used ... that are needed before a blood test could be ... & Dementia . The guidelines establish protocols and reflect ... includes UNT Health Science Center. "If we ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... the leading online,information source for life science ... launched the 2nd Edition of the Southern ... science community of the Southeastern,United States. The ... that constitute the dynamic biopharmaceutical industry in ...
... Celgosivir 4-Week Viral Kinetics Study Data on ... Monday December 3, ... Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results ...
... NOLabs AB, the Swedish,medtech company developing innovative ... Technology, today reported that it has,achieved another ... new line of,products for wounds infected by ... a bacterium that is particularly,troublesome in hospital-acquired ...
Cached Biology Technology:BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign 2MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria 2
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... stem cell research journals? This question has been ... Department of Neurosurgery and Brain Repair at the University of ... Stem Cell Reviews and Reports . Both Sanberg ... being published in the proliferating stem cell journals. ...
... herd of cattle is more than just cows. It,s a ... and hedge against drought. For many smallholder farmers, the loss ... Yet a grievous number of cattle in sub-Saharan Africa ... $40 billion, some twenty-five percent of the total value of ...
... Spring Harbor, NY -- One of the most tantalizing developments ... of targeted treatments, which have proven highly effective in holding ... for a limited period of time. A team led ... Harbor Laboratory (CSHL), today published results of a study that ...
Cached Biology News:Cow vaccines go vroom 2Cow vaccines go vroom 3New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered 2
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: